BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16919303)

  • 1. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
    Kobie K; Kawabata M; Hioki K; Tanaka A; Matsuda H; Mori T; Maruo K
    Res Vet Sci; 2007 Apr; 82(2):239-41. PubMed ID: 16919303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
    Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
    Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
    Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
    Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
    Stanclift RM; Gilson SD
    J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
    Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
    Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
    Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
    Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
    Taylor F; Gear R; Hoather T; Dobson J
    J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
    Floris G; Debiec-Rychter M; Sciot R; Stefan C; Fieuws S; Machiels K; Atadja P; Wozniak A; Faa G; Schöffski P
    Clin Cancer Res; 2009 Jun; 15(12):4066-76. PubMed ID: 19509176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypotonic water as adjuvant therapy for incompletely resected canine mast cell tumors: a randomized, double-blind, placebo-controlled study.
    Brocks BA; Neyens IJ; Teske E; Kirpensteijn J
    Vet Surg; 2008 Jul; 37(5):472-8. PubMed ID: 18986315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
    Kiupel M; Webster JD; Miller RA; Kaneene JB
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
    Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
    Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
    Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
    J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
    Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
    Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
    Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
    J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
    Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
    BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).
    Rassnick KM; Williams LE; Kristal O; Al-Sarraf R; Baez JL; Zwahlen CH; Dank G
    J Am Vet Med Assoc; 2008 Apr; 232(8):1200-5. PubMed ID: 18412534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.